Table 2 Univariable analysis of clinical variables with Cox proportional hazard model for DMFS and OS
Variables | DMFS | OS | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Gender (vs. Male) | ||||
Female | 1.70 (0.77–3.71) | 0.187 | 1.63 (0.75–3.55) | 0.221 |
Age (year) | 0.99 (0.96–1.02) | 0.616 | 1.00 (0.97–1.03) | 0.947 |
Previous cancer history (vs. No) | ||||
Yes | 0.59 (0.14–2.40) | 0.456 | 0.53 (0.13–2.18) | 0.383 |
Performance status (vs. ECOG 0–1) | ||||
ECOG 2–3 | 1.54 (0.37–6.32) | 0.552 | 2.43 (0.76–7.79) | 0.135 |
Differentiation (vs. Well to moderate) | ||||
Poorly differentiated | 0.85 (0.47–1.51) | 0.575 | 0.78 (0.45–1.36) | 0.381 |
Tumor length (cm) | 1.05 (0.94–1.16) | 0.400 | 1.05 (0.95–1.16) | 0.370 |
Tumor location (vs. Cervical-upper) | ||||
Middle to lower third | 0.71 (0.44–1.14) | 0.158 | 0.82 (0.52–1.27) | 0.366 |
Nodal stage (vs. N0-N1) | ||||
N2 | 1.05 (0.52–2.12) | 0.900 | 1.43 (0.72–2.86) | 0.311 |
N3 | 1.86 (0.90–3.84) | 0.090* | 2.06 (0.99–4.28) | 0.052* |
First course RT dose (vs. > = 40 Gy) | ||||
< 40 Gy | 1.72 (1.08–2.75) | 0.024** | 1.47 (0.94–2.28) | 0.091* |
Chemotherapy regimen (vs. Taxanes-based regimens) | ||||
Cisplatin + 5-FU | 2.30 (1.27–4.17) | 0.006** | 1.67 (0.99–2.81) | 0.053* |
SUVTumor | 1.00 (0.97–1.04) | 0.984 | 1.00 (0.96–1.03) | 0.848 |
SUVLN | 1.03 (1.00–1.07) | 0.026** | 1.03 (1.00–1.06) | 0.053* |
NTR (vs. Low NTR [<= 0.46]) | ||||
High NTR (> 0.46) | 2.17 (1.33–3.53) | 0.002** | 1.77 (1.12–2.79) | 0.014** |